Insilico expands Tenacia CNS alliance in $94.75M AI deal

Version 2

Insilico Medicine is widening its neuroscience push with a new expansion of its collaboration with Tenacia Biotechnology, a deal the companies say could be worth up to $94.75 million. Announced March 26, 2026, the updated agreement adds a second AI-driven CNS discovery program, with the partners aiming to develop an additional candidate for difficult neurological diseases and advance it to the preclinical candidate stage. (prnewswire.com)

The move builds on an earlier collaboration launched in March 2025. In that first phase, the companies combined Insilico’s Pharma.AI drug discovery platform with Tenacia’s CNS-focused expertise and proprietary data, targeting small-molecule inhibitors with strong blood-brain barrier permeability. That focus is notable because CNS drug development remains one of the toughest areas in biopharma, in part because getting therapeutics into the brain safely and effectively is still a major technical hurdle. (prnewswire.com)

Under the expanded terms, the partners said they will use generative AI to design a second candidate with differentiated properties against the same target area, with the goal of broadening therapeutic options and reducing late-stage development risk. Insilico said the added program carries potential value of up to $94.75 million through near-term and milestone payments. The company framed the rapid launch of a second program as evidence that its platform can generate multiple candidate profiles against a shared biology, rather than producing a single lead and stopping there. (prnewswire.com)

Tenacia brings a commercial-stage neuroscience focus and was founded in 2022 by Bain Capital, according to Bain Capital Life Sciences. Insilico, meanwhile, has been steadily building both its CNS footprint and its broader AI-drug-discovery business. In the Tenacia release, Insilico also pointed to its early-2026 co-development agreement with Hygtia Therapeutics around ISM8969 for CNS use, and said that program received FDA clearance in January 2026 to begin clinical trials in Parkinson’s disease. (prnewswire.com)

Industry context matters here. Just three days later, on March 29, 2026, Eli Lilly and Insilico announced a separate AI-driven collaboration worth up to $2.75 billion, including $115 million upfront, according to multiple reports. That doesn’t directly change the Tenacia deal, but it does suggest large pharma and biotech partners are increasingly willing to pay for access to AI-enabled discovery engines that can repeatedly generate programs across therapeutic areas. Inference: the Tenacia expansion likely benefits from that broader validation cycle, even though it remains a smaller, target-focused neuroscience partnership. (news.bloomberglaw.com)

The companies’ own comments were measured but pointed. Insilico CEO Alex Zhavoronkov said launching a second program with “differentiated attributes” on a short timeline shows the flexibility of generative AI in drug design, while Tenacia said the first year of work had shown the value of combining the two companies’ expertise. Those statements are promotional, but they align with a broader industry narrative: partners increasingly want proof that AI platforms can support iterative portfolio building, not just one-off discovery experiments. (prnewswire.com)

Why it matters: For veterinary professionals, this isn’t a practice-changing CNS story today. But it is a useful indicator of where biomedical R&D is heading. Platforms that improve hit finding, optimize for blood-brain barrier penetration, and generate differentiated small molecules faster could eventually influence comparative neurology, translational medicine, and animal health pipelines, especially in areas where canine and feline neurology overlap with human disease biology. Insilico has explicitly said its platform strategy extends beyond human therapeutics into veterinary medicine, making these human-sector collaborations worth watching as signals of future capability transfer. (prnewswire.com)

What to watch: The next markers will be whether the companies disclose the target, when they nominate a preclinical candidate, and whether Tenacia or Insilico publish any technical validation around brain-penetrant design. More broadly, watch whether Insilico’s recent run of CNS and large-pharma deals turns into a clearer animal health strategy, licensing activity, or cross-species neurology work over the next 12 to 24 months. (prnewswire.com)